CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of chronic diseases.
3.4.1.2. Advancement in nanotechnology
3.4.2. Restraints
3.4.2.1. Manufacturing Complexities
3.4.3. Opportunities
3.4.3.1. Government initiatives
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Lipid-based nanomedicine
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Polymer-based nanomedicine
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Nanocrystals
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oncology and Hematology
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Infectious diseases
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Orthopedics
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Neurology
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Urology
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Immunology
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
5.8. Others
5.8.1. Key market trends, growth factors and opportunities
5.8.2. Market size and forecast, by region
5.8.3. Market share analysis by country
CHAPTER 6: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. Market size and forecast, by Formulation
6.2.3. Market size and forecast, by Application
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Key market trends, growth factors and opportunities
6.2.4.1.2. Market size and forecast, by Formulation
6.2.4.1.3. Market size and forecast, by Application
6.2.4.2. Canada
6.2.4.2.1. Key market trends, growth factors and opportunities
6.2.4.2.2. Market size and forecast, by Formulation
6.2.4.2.3. Market size and forecast, by Application
6.2.4.3. Mexico
6.2.4.3.1. Key market trends, growth factors and opportunities
6.2.4.3.2. Market size and forecast, by Formulation
6.2.4.3.3. Market size and forecast, by Application
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Market size and forecast, by Formulation
6.3.3. Market size and forecast, by Application
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Key market trends, growth factors and opportunities
6.3.4.1.2. Market size and forecast, by Formulation
6.3.4.1.3. Market size and forecast, by Application
6.3.4.2. France
6.3.4.2.1. Key market trends, growth factors and opportunities
6.3.4.2.2. Market size and forecast, by Formulation
6.3.4.2.3. Market size and forecast, by Application
6.3.4.3. UK
6.3.4.3.1. Key market trends, growth factors and opportunities
6.3.4.3.2. Market size and forecast, by Formulation
6.3.4.3.3. Market size and forecast, by Application
6.3.4.4. Italy
6.3.4.4.1. Key market trends, growth factors and opportunities
6.3.4.4.2. Market size and forecast, by Formulation
6.3.4.4.3. Market size and forecast, by Application
6.3.4.5. Spain
6.3.4.5.1. Key market trends, growth factors and opportunities
6.3.4.5.2. Market size and forecast, by Formulation
6.3.4.5.3. Market size and forecast, by Application
6.3.4.6. Rest of Europe
6.3.4.6.1. Key market trends, growth factors and opportunities
6.3.4.6.2. Market size and forecast, by Formulation
6.3.4.6.3. Market size and forecast, by Application
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Market size and forecast, by Formulation
6.4.3. Market size and forecast, by Application
6.4.4. Market size and forecast, by country
6.4.4.1. China
6.4.4.1.1. Key market trends, growth factors and opportunities
6.4.4.1.2. Market size and forecast, by Formulation
6.4.4.1.3. Market size and forecast, by Application
6.4.4.2. Japan
6.4.4.2.1. Key market trends, growth factors and opportunities
6.4.4.2.2. Market size and forecast, by Formulation
6.4.4.2.3. Market size and forecast, by Application
6.4.4.3. India
6.4.4.3.1. Key market trends, growth factors and opportunities
6.4.4.3.2. Market size and forecast, by Formulation
6.4.4.3.3. Market size and forecast, by Application
6.4.4.4. Australia
6.4.4.4.1. Key market trends, growth factors and opportunities
6.4.4.4.2. Market size and forecast, by Formulation
6.4.4.4.3. Market size and forecast, by Application
6.4.4.5. South Korea
6.4.4.5.1. Key market trends, growth factors and opportunities
6.4.4.5.2. Market size and forecast, by Formulation
6.4.4.5.3. Market size and forecast, by Application
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Key market trends, growth factors and opportunities
6.4.4.6.2. Market size and forecast, by Formulation
6.4.4.6.3. Market size and forecast, by Application
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. Market size and forecast, by Formulation
6.5.3. Market size and forecast, by Application
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Key market trends, growth factors and opportunities
6.5.4.1.2. Market size and forecast, by Formulation
6.5.4.1.3. Market size and forecast, by Application
6.5.4.2. Saudi Arabia
6.5.4.2.1. Key market trends, growth factors and opportunities
6.5.4.2.2. Market size and forecast, by Formulation
6.5.4.2.3. Market size and forecast, by Application
6.5.4.3. South Africa
6.5.4.3.1. Key market trends, growth factors and opportunities
6.5.4.3.2. Market size and forecast, by Formulation
6.5.4.3.3. Market size and forecast, by Application
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Key market trends, growth factors and opportunities
6.5.4.4.2. Market size and forecast, by Formulation
6.5.4.4.3. Market size and forecast, by Application
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Abbvie Inc
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. Pfizer Ltd
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. AstraZeneca plc
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.4. Johnson & Johnson
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. Amgen Inc.
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.6. Merck KGaA
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.7. Nanobiotix SA
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Novartis AG
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.9. Teva Pharmaceutical Industries Limited
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.10. Bristol-Myers Squibb Company
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
TABLE 01. GLOBAL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 02. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR LIPID-BASED NANOMEDICINE, BY REGION, 2022-2032 ($MILLION)
TABLE 03. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR POLYMER-BASED NANOMEDICINE, BY REGION, 2022-2032 ($MILLION)
TABLE 04. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR NANOCRYSTALS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 07. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR ONCOLOGY AND HEMATOLOGY, BY REGION, 2022-2032 ($MILLION)
TABLE 08. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 09. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR ORTHOPEDICS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR NEUROLOGY, BY REGION, 2022-2032 ($MILLION)
TABLE 11. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR UROLOGY, BY REGION, 2022-2032 ($MILLION)
TABLE 12. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR IMMUNOLOGY, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NANOTECHNOLOGY DRUG DELIVERY MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 18. U.S. NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 19. U.S. NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. CANADA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 21. CANADA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. MEXICO NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 23. MEXICO NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 24. EUROPE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 25. EUROPE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. EUROPE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 27. GERMANY NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 28. GERMANY NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. FRANCE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 30. FRANCE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. UK NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 32. UK NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. ITALY NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 34. ITALY NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. SPAIN NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 36. SPAIN NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 37. REST OF EUROPE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 38. REST OF EUROPE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. ASIA-PACIFIC NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 40. ASIA-PACIFIC NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 41. ASIA-PACIFIC NANOTECHNOLOGY DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 42. CHINA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 43. CHINA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. JAPAN NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 45. JAPAN NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 46. INDIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 47. INDIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. AUSTRALIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 49. AUSTRALIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. SOUTH KOREA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 51. SOUTH KOREA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 53. REST OF ASIA-PACIFIC NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 54. LAMEA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 55. LAMEA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 56. LAMEA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 57. BRAZIL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 58. BRAZIL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. SAUDI ARABIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 60. SAUDI ARABIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 61. SOUTH AFRICA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 62. SOUTH AFRICA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. REST OF LAMEA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
TABLE 64. REST OF LAMEA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 65. ABBVIE INC: KEY EXECUTIVES
TABLE 66. ABBVIE INC: COMPANY SNAPSHOT
TABLE 67. ABBVIE INC: PRODUCT SEGMENTS
TABLE 68. ABBVIE INC: PRODUCT PORTFOLIO
TABLE 69. PFIZER LTD: KEY EXECUTIVES
TABLE 70. PFIZER LTD: COMPANY SNAPSHOT
TABLE 71. PFIZER LTD: PRODUCT SEGMENTS
TABLE 72. PFIZER LTD: PRODUCT PORTFOLIO
TABLE 73. PFIZER LTD: KEY STRATERGIES
TABLE 74. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 75. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 76. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 77. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 78. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 79. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 80. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 81. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 82. AMGEN INC.: KEY EXECUTIVES
TABLE 83. AMGEN INC.: COMPANY SNAPSHOT
TABLE 84. AMGEN INC.: PRODUCT SEGMENTS
TABLE 85. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 86. MERCK KGAA: KEY EXECUTIVES
TABLE 87. MERCK KGAA: COMPANY SNAPSHOT
TABLE 88. MERCK KGAA: PRODUCT SEGMENTS
TABLE 89. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 90. NANOBIOTIX SA: KEY EXECUTIVES
TABLE 91. NANOBIOTIX SA: COMPANY SNAPSHOT
TABLE 92. NANOBIOTIX SA: PRODUCT SEGMENTS
TABLE 93. NANOBIOTIX SA: PRODUCT PORTFOLIO
TABLE 94. NANOBIOTIX SA: KEY STRATERGIES
TABLE 95. NOVARTIS AG: KEY EXECUTIVES
TABLE 96. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 97. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 98. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 101. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 103. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 104. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 105. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 106. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
